Letter: Patents and cures for genetic disease
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sir: The Genetic Interest Group has not, does not and will not advocate the patenting of naturally occurring gene sequences. What we have been trying to achieve through our intervention in the European Parliament is a climate for investment in cures for genetic disease.
Your article is a distortion, not only of the draft directive's proposal, but also of the position that has been taken by the Genetic Interest Group and many other organisations.
What in fact we have been advocating is that gene sequences, when they form part of a diagnostic or therapeutic product and when they fulfil the other requirements of patentability, should potentially be patentable. In taking this approach we have been anxious to ensure that research funded by charities is protected, that the potential for diagnosis and treatment arising from this research is maximised and that those affected by currently incurable genetic disorders are able to have the best chance of benefiting from scientific progress in understanding the basic biology underlying their disease.
It is a fact that research is exempted under European patent law. It is a fact that the directive specifically excludes the patenting of naturally occurring gene sequences. It is a fact that the directive introduces valuable safeguards that will prevent unethical applications of genetic data and it is a fact that the directive introduces safeguards for animals used in research.
These are important developments that should be, and will be, welcomed by all who wish to see genetic disease finally vanquished.
ALASTAIR KENT
Director
Genetic Interest Group
London EC1
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments